A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Ebola Sudan Virus Disease
Interventions
BIOLOGICAL

cAd3-Sudan Vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.

BIOLOGICAL

Placebo

0.9% NaCl solution for injection.

Trial Locations (4)

32934

RECRUITING

Optimal Research; LLC, Melbourne

60602

RECRUITING

Synexus Clinical Research US, Inc., Chicago

78229

RECRUITING

Synexus Clinical Research US, Inc., San Antonio

85020

RECRUITING

Synexus Clinical Research US, Inc., Phoenix

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Albert B. Sabin Vaccine Institute

OTHER